Siemens Healthineers Stock Hits New Low as €6B Diagnostics Sale Gains Momentum

Siemens Healthineers stock plunges 20% YTD as it weighs €6B diagnostics sale to cut €14B debt, with a spin-off from Siemens AG looming in 2027.

The pressure on Siemens Healthineers is mounting from multiple directions. Shares of the German medtech group tumbled to a fresh 52-week trough of €35.20 on Friday, extending their year-to-date slide to roughly 20%. The sell-off comes as the company weighs a potential sale of its struggling diagnostics division, a move that could inject around €6 billion into its coffers.

That cash injection would be timely. The group is saddled with approximately €14 billion in debt, and a successful disposal would go a long way toward lightening that load. More importantly, it would allow management to zero in on the higher-margin imaging and cancer therapy businesses that have been carrying the weight.

The diagnostics unit has been a persistent drag on performance. Demand in China, a critical market, has softened considerably, and the division posted a noticeable decline at the start of the fiscal year. For the current quarter, executives have already tempered expectations, warning that revenue growth will fall short of the usual target range. Longer term, the company is banking on a recovery in Asia, projecting annual growth of around 5% in China from 2027 onward.

Operational headwinds are compounding the problem. Tariff threats are expected to cost the business up to €500 million in the current fiscal year, while currency fluctuations will eat another €200 million to €250 million out of operating earnings.

A Spin-Off Looms

The diagnostics review dovetails with a broader restructuring. Parent company Siemens AG is preparing to spin off a portion of its remaining stake in Healthineers, transferring 30% of the shares directly to its own shareholders. Siemens currently holds just over two-thirds of the medtech unit. The final vote on that separation is scheduled for February 2027.

A key piece of that puzzle fell into place recently. Moody’s assigned Healthineers an A3 credit rating, clearing the path for the company to issue its own bonds and finance itself independently of its parent. Until then, Healthineers must prove it can stand on its own two feet — and the diagnostics sale would be a powerful statement of intent.

Analysts See Value Despite the Pain

Wall Street has not thrown in the towel. The consensus price target sits at roughly €53, implying upside of more than 50% from current levels. Jefferies is even more bullish, maintaining a buy rating with a €60 target.

The next major catalyst arrives on May 7, when Healthineers reports second-quarter results. Investors will be looking for concrete updates on the diagnostics sale talks, as well as evidence that the full-year targets remain within reach. Management has stuck by its guidance for revenue growth of 5% to 6% and adjusted earnings per share of at least €2.20.

Whether the stock can climb back from its lows will depend on how convincingly the company navigates this maze of operational challenges, debt reduction, and corporate restructuring — all while keeping one eye on the exit door for its most troublesome division.